NCT00898794

Brief Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the effect of bevacizumab and VEGF on platelet clustering. PURPOSE: This research study is looking at the effect of bevacizumab and VEGF on platelet clustering in patients with cancer who are receiving bevacizumab.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2007

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2009

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

May 9, 2009

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 12, 2009

Completed
Last Updated

August 7, 2013

Status Verified

June 1, 2011

Enrollment Period

1.6 years

First QC Date

May 9, 2009

Last Update Submit

August 6, 2013

Conditions

Unspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol Specific

Keywords

unspecified adult solid tumor, protocol specificunspecified childhood solid tumor, protocol specific

Outcome Measures

Primary Outcomes (4)

  • Influence of bevacizumab on platelet aggregation

  • Influence of VEGF on platelet aggregation

  • Influence of VEGF or bevacizumab on cyclooxygenesis

  • Correlation between medication sequence and platelet aggregation

Interventions

bevacizumabBIOLOGICAL
coagulation studyOTHER
laboratory biomarker analysisOTHER
platelet aggregation testOTHER

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
DISEASE CHARACTERISTICS: * Receiving bevacizumab for cancer PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

Kantonsspital Graubuenden

Chur, CH-7000, Switzerland

RECRUITING

MeSH Terms

Interventions

BevacizumabBleeding TimePlatelet Aggregation

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulinsPlatelet Function TestsHematologic TestsClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative TechniquesBlood Physiological PhenomenaCirculatory and Respiratory Physiological PhenomenaHemorheologyPlatelet ActivationHemostasis

Study Officials

  • Roger von Moos, MD

    Kantonsspital Graubuenden

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 9, 2009

First Posted

May 12, 2009

Study Start

October 1, 2007

Primary Completion

May 1, 2009

Last Updated

August 7, 2013

Record last verified: 2011-06

Locations

CH(1)